Multi-Layer Biological Network Analysis for Predicting Synergistic Interactions Among Bioactive Compounds in Neurodegenerative Diseases

Authors

  • Eliza Reijers Department of Computer Science, University of Alabama at Birmingham, Birmingham, AL, USA. Author
  • Niek de Gruijter Department of Electrical Engineering and Computer Science, University of Missouri, Columbia, MO, USA. Author

Keywords:

multilayer networks; network pharmacology; synergy prediction; graph neural networks; neurodegenerative disease; uncertainty calibration

Abstract

Neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease involve interacting proteinopathies, mitochondrial dysfunction, neuroinflammation, impaired proteostasis, and synaptic failure, yet most therapeutic discovery pipelines still prioritize single targets. Bioactive compounds with multi-target profiles are plausible combination partners, but predicting which compound pairs act synergistically remains difficult because compound-target, pathway-disease, and disease-disease relations are heterogeneous and incompletely observed. This manuscript develops a multi-layer biological network framework for predicting synergistic interactions among bioactive compounds in neurodegenerative disease contexts. The framework represents compounds, proteins, pathways, disease modules, and phenotypes across relation-specific layers; aligns them through shared biological entities; and combines chemical similarity, target engagement, pathway crosstalk, network propagation, and disease-module proximity. A relation-aware graph neural network estimates compound-pair and disease-specific synergy probabilities, while a multi-task objective enforces prediction symmetry, layer regularization, and class-imbalance correction. Uncertainty is quantified through ensemble variance, and candidate prioritization requires both a lower confidence bound and a mechanistic concordance criterion. The paper specifies label construction from Loewe or Bliss reference models, calibration procedures, scaffold and disease-held-out validation, negative-sampling controls, and domain-specific failure modes. The contribution is a falsifiable and auditable integration of multilayer network biology, synergy theory, and uncertainty-aware machine learning that can guide experimental combination screening in neurodegenerative disease research.

References

1. Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science, 297(5580), 353–356. https://doi.org/10.1126/science.1072994

2. Dugger, B. N., & Dickson, D. W. (2017). Pathology of neurodegenerative diseases. Cold Spring Harbor Perspectives in Biology, 9(7), a028035. https://doi.org/10.1101/cshperspect.a028035

3. Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019). Ageing as a risk factor for neurodegenerative disease. Nature Reviews Neurology, 15(10), 565–581. https://doi.org/10.1038/s41582-019-0244-7

4. Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017). Parkinson disease. Nature Reviews Disease Primers, 3, 17013. https://doi.org/10.1038/nrdp.2017.13

5. Hopkins, A. L. (2008). Network pharmacology: The next paradigm in drug discovery. Nature Chemical Biology, 4(11), 682–690. https://doi.org/10.1038/nchembio.118

6. Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011). Network medicine: A network-based approach to human disease. Nature Reviews Genetics, 12(1), 56–68. https://doi.org/10.1038/nrg2918

7. De Domenico, M., Solé-Ribalta, A., Cozzo, E., Kivelä, M., Moreno, Y., Porter, M. A., Gómez, S., & Arenas, A. (2013). Mathematical formulation of multilayer networks. Physical Review X, 3(4), 041022. https://doi.org/10.1103/PhysRevX.3.041022

8. Kivelä, M., Arenas, A., Barthelemy, M., Gleeson, J. P., Moreno, Y., & Porter, M. A. (2014). Multilayer networks. Journal of Complex Networks, 2(3), 203–271. https://doi.org/10.1093/comnet/cnu016

9. Li, S., & Zhang, B. (2013). Traditional Chinese medicine network pharmacology: Theory, methodology and application. Chinese Journal of Natural Medicines, 11(2), 110–120. https://doi.org/10.1016/S1875-5364(13)60037-0

10. Loewe, S. (1953). The problem of synergism and antagonism of combined drugs. Arzneimittelforschung, 3(6), 285–290.

11. Bliss, C. I. (1939). The toxicity of poisons applied jointly. Annals of Applied Biology, 26(3), 585–615. https://doi.org/10.1111/j.1744-7348.1939.tb06990.x

12. Chou, T.-C., & Talalay, P. (1984). Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27–55. https://doi.org/10.1016/0065-2571(84)90007-4

13. Zitnik, M., Agrawal, M., & Leskovec, J. (2018). Modeling polypharmacy side effects with graph convolutional networks. Bioinformatics, 34(13), i457–i466. https://doi.org/10.1093/bioinformatics/bty294

14. HerbSyner_Finder: a network community-based model for identifying synergistic combinations from herbal medicines and complex systems. Targetome. 2026;2(2):0-0. doi: 10.48130/targetome-0026-001

15. Veličković, P., Cucurull, G., Casanova, A., Romero, A., Liò, P., & Bengio, Y. (2017). Graph attention networks. arXiv:1710.10903. https://arxiv.org/abs/1710.10903

16. Gilmer, J., Schoenholz, S. S., Riley, P. F., Vinyals, O., & Dahl, G. E. (2017). Neural message passing for quantum chemistry. arXiv:1704.01212. https://arxiv.org/abs/1704.01212

17. Kipf, T. N., & Welling, M. (2016). Semi-supervised classification with graph convolutional networks. arXiv:1609.02907. https://arxiv.org/abs/1609.02907

18. Himmelstein, D. S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S. L., Hadley, D., Green, A. J., Khankhanian, P., & Baranzini, S. E. (2017). Systematic integration of biomedical knowledge prioritizes drugs for repurposing. eLife, 6, e26726. https://doi.org/10.7554/eLife.26726

19. Guney, E., Menche, J., Vidal, M., & Barabási, A.-L. (2016). Network-based in silico drug efficacy screening. Nature Communications, 7, 10331. https://doi.org/10.1038/ncomms10331

20. Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., & Zhao, S. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 18(6), 463–477. https://doi.org/10.1038/s41573-019-0024-5

21. Ryu, J. Y., Kim, H. U., & Lee, S. Y. (2018). Deep learning improves prediction of drug-drug and drug-food interactions. Proceedings of the National Academy of Sciences of the United States of America, 115(18), E4304–E4311. https://doi.org/10.1073/pnas.1803294115

22. Menche, J., Sharma, A., Kitsak, M., Ghiassian, S. D., Vidal, M., Loscalzo, J., & Barabási, A.-L. (2015). Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science, 347(6224), 1257601. https://doi.org/10.1126/science.1257601

Downloads

Published

2026-11-06